GlassScriptPhysician profile
Ronald D Tamaru
NPI 1477631166
$2,177.44
in general payments reported to CMS, 2019-2025
12 companies · $527 in 2025
The $527 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $331 · 2022: $248 · 2023: $243 · 2024: $828 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,598.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $276.48 | 2024-2025 | Omni Surgical System |
| Horizon Therapeutics Plc | $249.37 | 2022-2023 | Tepezza |
| Apellis Pharmaceuticals, INC. | $243.19 | 2024-2025 | Syfovre |
| Alcon Vision LLC | $237.77 | 2023-2024 | Clareon |
| Amgen INC. | $222.10 | 2024-2025 | Tepezza |
| New World Medical,INC. | $199.65 | 2024 | Streamline, Kahook Dual Blade, Ahmed Glaucoma Valve |
| Heidelberg Engineering, INC. | $184.27 | 2021 | |
| Glaukos Corporation | $164.67 | 2025 | Idosetr |
| Astellas Pharma US INC | $129.69 | 2024 | Izervay |
| Biotissue Holdings INC. | $123.31 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $112.49 | 2021 | |
| Eyepoint US, INC. | $34.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Tamaru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.